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Background: Necrotizing soft tissue infections (NSTIs) are rare but carry a high
morbidity and mortality. The multicenter INFECT project aims to improve the under-
standing of the pathogenesis, clinical characteristics, diagnosis, and prognosis of
NSTIs. This article describes the study outline and statistical analyses that will be
used.
Methods: Within the framework of INFECT project, patients with NSTI at 5 Scandi-
navian hospitals are enrolled in a prospective observational cohort study. The goal is
to evaluate outcome and characteristics for patients with NSTI and diabetes com-
pared to patients with NSTI without diabetes. The primary outcome is mortality at
90 days after inclusion. Secondary outcomes include days alive and out of ICU and
hospital, SAPS II, SOFA score, infectious etiology, amputation, affected body area, and
renal replacement therapy. Comparison in mortality between patients with diabetes
type 1 and 2 as well as between insulin-treated and non-insulin–treated diabetes
patients will be made. Clinical data for diabetic patients with NSTI will be reported.
Conclusion: The study will provide important data on patients with NSTI and
diabetes.
1 | INTRODUCTION
1.1 | Necrotizing soft tissue infections
Necrotizing soft tissue infections (NSTIs) are uncommon, severe, and
potentially lethal conditions.1,2 Surviving often comes at the prize of
life-lasting morbidity.3 NSTI typically presents with pain, swelling,
and skin discoloration4. The infection may involve any layer of soft
tissue, causing local ischemia, tissue destruction, and necrosis.4-6
Bacterial spread proceeds swiftly, frequently along fascial planes.
Host immunological response results in systemic toxicity. Shock,
organ failure, and eventually death may result.7-9
Microbiological findings frequently exhibit a distinguishing pat-
tern with polymicrobial growth in samples from the pelvic region10,11†INFECT Study Group members are in Appendix 1.
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and monomicrobial growth when a limb is affected. In the latter
case, group A streptococcus is often found in cultures, but many
other bacterial findings have been described as well.4,12-14
Mainstays of successful treatment are aggressive resuscitation,
intravenous antibiotics, and prompt surgical resection of affected tis-
sue.4,6,8,10,12 Hyperbaric oxygen treatment (HBOT) is, by some, con-
sidered an adjuvant treatment resource.8,15,16 Due to concurrent
circulatory, respiratory, and renal disturbances, most patients are
treated at intensive care units (ICU).
Diabetes is associated with an increased risk of infections4,17,18
and is overrepresented among patients with NSTI, with a reported fre-
quency of 20%-70%.10,11,15,19-23 In contrast, the World Health Organi-
zation (WHO) estimates global diabetes prevalence to be 8.5% in
adults.24 Concomitant diabetes seems to be a negative prognostic fac-
tor among patients with NSTI with increased risk of death, amputation,
and infectious complications.22,23,25-27 Hyperglycemia could be a fac-
tor associated with outcome in diabetic patients with NSTI.26
1.2 | Hypothesis
Our research hypothesis is that there are significant differences in
both clinical characteristics, bacterial findings, and outcome among
patients with NSTI and diabetes compared to patients with NSTI
without diabetes.
1.3 | Study aim
The aim of this study is to report outcome for patients with NSTI
and diabetes compared to patients with NSTI without diabetes and
to report clinical data for patients with NSTI and diabetes.
2 | METHODS
2.1 | Study design
Prospective observational cohort study.
2.2 | Population
Adult (≥18 years) patients with NSTI.
2.3 | Exposure group
Patients with diabetes type 1 or type 2.
2.4 | Comparison group
Patients without diabetes type 1 or type 2.
2.5 | Outcome
2.5.1 | Primary outcome
1. All-cause mortality 90 days after inclusion.
2.5.2 | Secondary outcomes
1. Days alive and out of ICU at day 30 after inclusion.
2. Days alive and out of hospital at day 90 after inclusion.
3. Amputation of the extremities during ICU stay.
Site of amputation is defined as either upper arm, lower arm,
hand, finger, upper leg, lower leg, foot, toe, or penis.
4. Sequential organ failure assessment score (SOFA score) day 1 in
the ICU.
SOFA score is used to measure severity of disease. It is based
on the assessed function of respiratory, nervous, and cardiovas-
cular systems, liver, kidneys, and coagulation.28,29
5. SAPS II score at ICU admission.
SAPS II score is used to measure severity of disease at ICU
admission. It is based on measured physiological parameters and
results from blood samples, previous health status, and informa-
tion about the ICU admission.30
6. The presence of monomicrobial growth of group A streptococci
(GAS) in cultures.
Tissue and blood samples taken at referring hospital and study
hospital are used.31
7. The presence of monomicrobial growth of group B streptococci
in cultures.
Tissue and blood samples taken at both referring hospital and
study hospital are used.31
8. The presence of monomicrobial growth of Staphylococcus aureus
in cultures.
Tissue and blood samples taken at both referring hospital and
study hospital are used.31
9. The presence of polymicrobial flora in cultures.
Tissue and blood samples taken at both referring hospital and
study hospital are used.31
10. Affected body area at inclusion.
Affected body area is defined as either head and neck, upper
body (including upper extremities), abdomen and anogenital
region, or lower extremities.
11. Any renal replacement therapy (RRT) within 90 days after
inclusion.
RRT is defined as either intermittent hemodialysis or continuous
renal replacement therapy.
2.5.3 | Exploratory outcomes
Comparisons are made within the group of patients with diabetes
type 1 and type 2:
1. Association between glycated hemoglobin (A1C) values before
admission and all-cause mortality 90 days after inclusion.
2. All-cause mortality 90 days after inclusion in patients with dia-
betes type 1 compared to patients with diabetes type 2.
3. All-cause mortality 90 days after inclusion in patients with insu-
lin-treated diabetes (type 1 and type 2) compared to non-insulin–
treated patients with diabetes type 2.
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4. Association between A1C values before admission and days alive
and out of ICU at day 30 after inclusion.
5. Association between A1C values before admission and the pres-
ence of polymicrobial flora in cultures.
Tissue and blood samples taken at both referring hospital and
study hospital are used.31
6. Association between A1C values before admission and affected
body area at inclusion.
Affected body area is defined as either head and neck, upper
body (including upper extremities), abdomen and anogenital
region, or lower extremities.
7. Association between A1C values before inclusion and any RRT
within 90 days after inclusion.
RRT is defined as either intermittent hemodialysis or continuous
renal replacement therapy.
2.5.4 | Reported clinical data, comorbidities, risk
factors for NSTI, and medication
-Sex;
-Age;
-Weight (before surgery; if not available then best estimate);
-Body mass index;
-Smoking habits (currently smoking/estimated package years);
-AIDS (HIV positive with clinical complications as Pneumocystis jiro-
veci pneumonia, Kaposi’s sarcoma, lymphoma, tuberculosis, or toxo-
plasma infection);
-Other immunodeficiencies;
-Active malignancy;
-Metastatic carcinoma (proven metastasis by surgery, CT scan, or
any other method);
-Hematologic cancer;
-Chronic obstructive pulmonary disease (COPD) or asthma;
-Current or previous cardiovascular disease (hypertension, myocardial
infarction, angina pectoris, heart failure, apoplexy);
-Peripheral vascular disease;
-Diabetes type 1;
-Non-insulin–treated diabetes type 2;
-Insulin-treated diabetes type 2;
-Chronic kidney disease (s-creatinine > 100 before admission for
NSTI or any kind of dialysis);
-Chronic liver disease (any history of chronic liver disease);
-Varicella;
-Rheumatoid disease;
-Previously admitted for necrotizing soft tissue infection;
-Surgery within the previous 4 weeks;
-Blunt trauma (a hit by a blunt object or a fall within the 4 weeks
prior to diagnosis);
-Penetrating trauma (a hit by a sharp object penetrating the skin
within the 4 weeks prior to diagnosis);
-Chronic wound or other skin disease;
-Intravenous drug use;
-Immunosuppressive drugs given for rheumatoid disease or malig-
nant disease;
-Steroids.
2.6 | The INFECT project
Improving Outcome of Necrotizing Fasciitis: Elucidation of Complex
Host and Pathogen Signatures that Dictate Severity of Tissue Infection
(INFECT) is an international, prospective, multicenter observational
research project. The goal is to improve the understanding of the patho-
genesis, clinical characteristics, diagnosis, and prognosis of NSTIs.32
Within the framework of INFECT, patients are recruited from 5 Scandi-
navian hospitals which are all referral hospitals for patients with NSTI.
INFECT is registered at ClinicalTrials.gov (NCT01790698).
2.7 | Study setting
Patients are recruited from intensive care departments in the follow-
ing hospitals:
Copenhagen University Hospital, Rigshospitalet, Copenhagen,
Denmark.
Sahlgrenska University Hospital/Ostra, Gothenburg, Sweden.
Karolinska University Hospital, Stockholm, Sweden.
Blekinge County Council Hospital, Karlskrona, Sweden.
Haukeland University Hospital, Bergen, Norway.
2.8 | Eligibility
Patients arriving at a study hospital during the study period with a
suspected NSTI are eligible for inclusion.
2.9 | Inclusion criteria
Adult (≥18 years) patients with confirmed NSTI treated in one of the
participating hospitals who consent to participate in the study.
The diagnosis of NSTI is made by the surgeon during the primary
operation. It is based on, but not restricted to, findings of necrosis, dis-
solved or deliquescent soft tissue, and fascial and muscular affection.
2.10 | Exclusion criteria
Denial or withdrawal of consent.
Later refuted NSTI diagnosis.
2.11 | Subject enrollment
Patients are included by local research staff at each hospital. Con-
sent is obtained according to national ethical regulations.
The research staff ensures that the consenting party is given
oral and written information approved by the respective ethical
committee about the nature, purpose, possible risk, and benefit of
the study.
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2.12 | Group allocation (exposure/comparison)
Patients with an existing diagnosis of diabetes type 1 or type 2 in
the medical records before inclusion in the study are allocated to
the exposure group.
Patients without an existing diagnosis of diabetes type 1 or type
2 in the medical records before inclusion in the study are allocated
to the comparison group.
2.13 | Timeline
The first patient was included in February 2013 and the last patient
was included in June 2017. Patients’ data registration is planned to
be completed in March 2018.
2.14 | Data collection methods
Data are obtained from hospital medical records, hospital laborato-
ries, and official death registries. Participation in the study results in
additional blood sampling and extended collection of specimens for
microbiological analysis.
2.15 | Registered variables
Description of clinical variables registered in the INFECT project
including principles of bacterial categorization are available in a sepa-
rate publication.31
Among patients with diagnosed diabetes, available A1C values
from up to 6 months before inclusion are retrospectively collected
from medical records.
Also in retrospect, patients with diabetes will be categorized as
type 1, insulin-treated type 2, or non-insulin–treated type 2 based
on information from medical records.
2.16 | Data management
All research data are handled confidentially and in accordance with
national laws and regulations. Patients’ data are anonymized, using
an individual study code. Code lists are kept locked up and separate
from registered study data. Original records will be retained at trial
sites for the time specified by national regulations.
A common electronical database (eCRF) with all recorded data is
kept in Copenhagen, Denmark (Danish Data protection Agency
approval 30-0900). The trial database will be maintained for
15 years.
2.17 | Missing data
2.17.1 | Imputation
We will perform complete-case analyses. If the frequency of miss-
ing data for a given analysis is more than 5%, the analysis will be
repeated using multiple imputation based on chained equations
(MICE). The variables included in the multiple imputation will be
age, SOFA score at day 1, the presence of hematological cancer,
presence of diabetes, presence of chronic obstructive pulmonary
disease (COPD) or asthma, presence of current or previous cardio-
vascular disease, presence of chronic kidney disease, GAS found
in cultures and 90-day mortality. The variables used in specific
analyses will be excluded from the imputation. We will also pre-
sent unadjusted, non-imputed analyses.
2.17.2 | SAPS II score
If values from admission blood samples are missing, values from day
2 will be used.
2.17.3 | SOFA score
If values from blood samples at day 1 are missing, values from day 2
will be used. Due to the nature of eCRF, day 1 can vary from 0 to
24 hours. If day 1 is <12 hours, the worst value from either day 1 or
day 2 is used. The SOFA score has been modified, as Glasgow Coma
Scale (GCS) is not included.
2.17.4 | Diabetes type and A1C
If the amount of missing data exceeds 20%, the specific analysis will
not be performed.
3 | STATISTICAL METHODS
3.1 | General analytical principles
For all analyses, the level of statistical significance (2-sided) is 0.05.
P-values will be adjusted for multiple testing by the Benjamini-Hoch-
berg method.
3.2 | Outcomes
3.2.1 | Primary outcome
The primary outcome (all-cause mortality 90 days after inclusion)
expressed as dichotomous variable (0-1) will be analyzed by logistic
regression with 90 days mortality as response, having diabetes (di-
chotomous variable) as regressor and considering age (in years) as a
covariate. Data will be presented as relative risks (RR) including 95%
confidence intervals (CI).
3.2.2 | Secondary outcomes
The secondary outcomes will be analyzed by Fisher’s exact test for
categorical variables (amputation, affected body area, and renal
replacement therapy) and by Mann-Whitney-Wilcoxon test for the
continuous variables (SOFA score and SAPS II). Specific considera-
tions are mentioned below.
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Number of days alive and out of hospital at day 90 and days
alive and out of ICU at day 30 will be analyzed by Mann-Whitney-
Wilcoxon test.
The presence of specific bacterial species in cultures of blood
or tissue expressed as dichotomous variables (0-1) will be ana-
lyzed by logistic regression considering affected body area at
admission as covariates. Data will be presented as RR including
95% CI.
3.2.3 | Exploratory outcomes
All-cause mortality at 90 days expressed as dichotomous variable
(0-1) will be analyzed by logistic regression with mortality at
90 days as response and considering age (in years) as a covariate.
Regressors will be either dichotomous variables (diabetes sub-
groups: type 1 and type 2 or insulin-treated and non-insulin–trea-
ted) or a continuous variable (A1C values before admission)
depending on the outcome of interest. Data will be presented as
RR including 95% CI.
The exploratory outcomes investigating association with A1C val-
ues before admission will be analyzed by Mann-Whitney-Wilcoxon
test for continuous variables (number of days alive and out of ICU)
and Fisher’s exact test for categorical variables (affected body area,
renal replacement therapy). Specific considerations are mentioned
below.
The presence of specific bacterial species in cultures of blood or
tissue expressed as dichotomous variables (0-1) will be analyzed by
logistic regression considering affected body area at admission as
covariates. Data will be presented as RR including 95% CI.
3.2.4 | Clinical data, comorbidities, risk factors for
NSTI, and medication
Data will be presented as number/total number (percentage), median
(IQR), or mean (SD).
3.3 | Sample size estimation and sensitivity analysis
A total of 400 patients or more are expected to be included. Esti-
mating a diabetes incidence between 25% and 35%, the group
sizes will range between N1 = 100 and 140 for the diabetics and
N2 = 300 and 260 for the nondiabetics.
Sensitivity analysis was performed with G*Power.33
With a power of 0.8 and a confidence level a = 0.05, the small-
est difference in proportions estimated with a Fisher0s exact test
range between 7% and 12.5% both for N1/N2 = 100/300 and N1/
N2 = 140/260.
For differences in mean, estimated with Mann-Whitney-Wil-
coxon, the smallest estimable effect is 0.29 for N1/N2 = 100/300
and 0.27 for N1/N2 = 140/260.
For odds ratios calculated by estimating logistic regression, the
estimable odds ratios are either smaller than 0.49 or higher than
1.80 for N = 400.
4 | DISCUSSION
Diabetes is a common disease worldwide. Its impact on outcome
among patients with NSTI is reported to be negative. This study will
provide clinical data regarding diabetes frequency and outcome for
patients with diabetes in a prospective Scandinavian NSTI cohort
study. The cohort will, compared to earlier studies, be large. The
prospective design of the study is a strength, yet the observational
design precludes causative conclusions.
An unknown number of patients will likely be misclassified as
nondiabetics. They represent individuals who, before developing
NSTI, would have fulfilled the diagnostic criteria for diabetes type 2,
but had yet not received a diagnosis.
Metabolic control before hospitalization as well as type of
diabetes (type 1 or 2) and treatment (insulin or non-insulin)
might influence outcome in NSTI. There are numerous flaws
connected to using retrospective A1C values. Nothing is known
of the clinical circumstances when the A1C samples were col-
lected. The time elapsed between A1C sample acquisition and
hospital admission will be variable among patients. This, in com-
bination with missing A1C values, makes estimation of blood
glucose control before admission unreliable. Retrospective cate-
gorization of diabetes type and its treatment (insulin, non-insulin)
for each included patient might be either not feasible or incor-
rect. Therefore, results from exploratory outcomes must be
interpreted with caution.
Certain patient comorbidities, for example, peripheral vascular
disease and chronic liver disease, are not clearly defined in the study
protocol. This entails subjectivity and a risk of bias when registering
patient data.
The use of 4 arbitrarily defined body areas to describe the infec-
tious locus makes data compilation and statistical analysis easier.
However, all categorization results in loss of information and
reduced precision.
There is a relatively high number of secondary and exploratory
outcomes. Statistical adjustment for multiple testing is used to
reduce this risk of falsely positive findings. The amount of patients
eligible for calculation of the exploratory outcomes will probably
only number about 100-120, making statistical inference less
precise.
Despite its limitations, this study will provide important data on
patients with NSTI and diabetes.
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Patients get no direct benefit from participation in the study.
Hopefully results from the study will lead to improved treatment for
diabetic patients with NSTI in the future.
PUBLICATION
Resultswillbereported inaccordancewithSTROBEguidelinesforcohort
studies34andsubmittedforpublication inapeer-reviewedjournal.
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